A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex (R)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Abstract

Sativex treatment resulted in a significant reduction in treatment-resistant spasticity, in subjects with advanced MS and severe spasticity. The response observed within the first 4 weeks appears to be a useful aid to prediction of responder/non- status.

Keywords

• cannabidiol
• cannabinoids
• delta-9-tetrahydrocannabinol
• endocannabinoid system
• multiple sclerosis
• nabiximols
• Sativex
• spasticity